Evaluation of the incidence venous and arterial thromboembolism and its impact on overall survival in patients with bladder cancer treated with immune checkpoint inhibitors
Latest Information Update: 24 Aug 2022
At a glance
- Drugs Atezolizumab (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Bladder cancer
- Focus Adverse reactions; Therapeutic Use
Most Recent Events
- 20 Aug 2022 Results published in the Targeted Oncology
- 19 Jun 2020 New trial record
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology